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Abstract
Background: The purpose of this study was to investigate the frequency and the distribution of inflammatory cell
infiltrate in two sets of cutaneous biopsies derived from clinically affected and unaffected skin in patients with
systemic sclerosis (SSc) and to test correlation between the cell infiltrate and the progression of skin involvement.
Methods: Skin was immunohistochemically assessed to identify CD68, CD3, CD20 and CD138-positive (+) cells in
clinically affected and unaffected skin in 28 patients with SSc. Patients were followed for 6 months and the
characteristics of the infiltrate were analyzed according to disease duration, clinical features and skin involvement
progression.
Results: In all SSc cutaneous specimens, cellular infiltrates were found in a perivascular location predominantly
in the mid and deeper portions of the dermis. All the analyzed biopsies showed a CD3+ and CD68+ cell infiltrate
and the mean number of CD3+ and of CD68+ cells was higher in clinically involved skin (CD3+, 71.7 ± 34.6 and
CD68+, 26.3 ± 8.4, respectively) than in clinically uninvolved skin (CD3+, 45.7 ± 36.0 and CD68+, 13.6 ± 6.1,
respectively) (p < 0.001 for both comparisons). CD20+ cells were found in 17 (60.7%) patients and in these patients
the mean number of CD20+ cells was higher in clinically involved (4.7 ± 5.9) than in uninvolved skin (1.9 ± 2.9),
(p = 0.04). There was a greater number of CD20+ cells in patients with early SSc compared with patients with
long-standing disease. CD138+ cells were found in 100% of biopsies of clinically involved skin and in 89.3% of
biopsies of uninvolved skin. The mean number of CD138+ cells was higher in clinically involved skin (3.6 ± 2.3)
than in clinically uninvolved skin (1.9 ± 1.7), (p < 0.001). Seven patients experienced more than 20% worsening
in the skin score after 6 months of follow up; all of them had a CD20+ skin infiltrate on biopsy of clinically
involved skin.
Conclusions: Our results confirm that mononuclear cells are present in the skin of all patients with SSc, underlining
the role of inflammatory cell infiltrates in skin involvement in SSc. B cells in the skin seem to characterize patients
with early diffuse skin disease and to correlate with skin progression.
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Background
Progressive systemic sclerosis (SSc) or scleroderma is a
chronic connective tissue disorder characterized by vascular
and cellular abnormalities that predominate in the early
stages of disease and eventually lead to extensive cutaneous
and visceral fibrosis, which is most prominent in the later
stages [1–3]. The pathologic phenotype of the disease is
complex and, consequently, its etiology and the effective
therapies to prevent its progression remain elusive.
Cutaneous mononuclear cells are a frequent histo-
pathological finding in SSc. Previous studies have re-
corded an increase in the number of mast cells [4, 5],
macrophages [3, 6–11] and T lymphocytes [3, 6, 8–12],
in particular in the early stages of SSc. Furthermore,
microarray analysis in the lungs and in the skin of pa-
tients with scleroderma indicates overexpression of
macrophage marker genes [13–16]. In vitro studies have
demonstrated that all these cells can produce several cy-
tokines and stimulate fibroblasts [1].
To date, although there have been various reports of
studies of the B cell infiltrate in SSc [3, 6, 8–10, 13, 17–19],
its characterization in skin affected by scleroderma is still
incomplete. Recently, some encouraging results suggested a
possible use of an anti-CD20 monoclonal antibody (rituxi-
mab) for the treatment of early, progressive and diffuse
scleroderma, suggesting a role for B cells in the pathogen-
esis of the disease in the early stage [17–23]. In fact, it has
been shown that patients with SSc present with autoanti-
body production [24], hyper-γ-globulinemia, polyclonal B
cell hyperactivity [25] and abnormalities in the B cell com-
partments, characterized by an increase in naïve cells and a
decrease in activated memory B cells [26]. In addition, in
scleroderma there is markedly increased expression of
CD19, a signal transduction molecule of B cells that regu-
lates production of autoantibodies, in both memory and
naïve B cells [26, 27]. In patients with diffuse SSc (dSSc),
analysis of DNA microarrays of cutaneous biopsies have
demonstrated higher expression of clusters of genes of
CD20+ cells and of plasma cells [13].
In an attempt to further clarify the characteristics of
the cellular infiltrate, and mostly the possible role of B
cells in skin fibrosis, we investigated the frequency and
the distribution of mononuclear cells in two sets of cuta-
neous biopsies derived from clinically affected and un-
affected skin from patients with SSc. The characteristics
of the infiltrate were also analyzed according to disease
duration, clinical features of the patients and skin score
modification after 6 months.
Methods
Patients
Patients with SSc (n = 28 (24 female and 4 male)) attend-
ing the outpatient clinic of the Division of Rheumatology
of our institution agreed to undergo skin biopsies on both
clinically affected and unaffected skin and were included
in the study. All patients fulfilled the old and the new
classification criteria for scleroderma proposed by the
European League Against Rheumatism (EULAR) and the
American College of Rheumatology (ACR) [28, 29]. In-
formed signed consent to undergo biopsies and to provide
skin samples and clinical data for research purposes was
provided by all the patients. This research has been per-
formed in accordance with the Declaration of Helsinki
and it was approved by our institutional ethics committee
(Comitato Etico Università Cattolica del Sacro Cuore
1883/12).
Demographic and clinical characteristics were col-
lected in all patients with SSc enrolled in the study. Pa-
tients were grouped according to the classification
proposed by LeRoy in patients with limited SSc (lSSc) or
diffuse SSc (dSSc) [30]. The extent of skin involvement
was evaluated by the Rodnan skin score, performed by
two assessors (always the same at every evaluation)
whose results were averaged [31], at the time of skin bi-
opsy and after a mean follow-up time of 6.5 ± 0.8
months. A modification of skin score higher than 20%
was considered clinically significant progression [32, 33].
Antinuclear antibodies (ANA) were determined by indir-
ect immunofluorescence using Hep-2 cells as substrates
and autoantibody specificities were further assessed by
ELISA (Shield, Dundee, UK).
Cutaneous specimens were taken from patients with
SSc, by surgical excision with a 6-mm punch from the dis-
tal forearm for the clinically involved skin (skin score >1
at this site) and from the buttock for clinically uninvolved
skin (skin score = 0 at this site). The presence of mono-
nuclear inflammatory cells was investigated in all skin
specimens, in particular CD3 as a marker of T lympho-
cytes, CD20 as a marker of B-lymphocytes (local mature B
cells and memory B cells), CD138 as a marker of plasma
cells and CD68 as a marker of residential macrophages.
At the time of the skin biopsies, the activity index [34]
and the severity index [35] were assessed and Global
Health (GH) status and Health Assessment Question-
naires (HAQ) were administered to patients to evaluate
the influence of the disease on daily functions.
All 28 patients continued to receive iloprost (an infu-
sion of 0.5–2 ng/kg body weight/min for 5 days every 2
months), calcium channel blockers (nifedipine 20–40
mg/day) and acetylsalicylic-acid from the moment of
diagnosis. Patients receiving corticosteroids or immuno-
suppressive drugs at the time of skin biopsy were ex-
cluded from the study. During the follow-up period, 12
patients were treated with anti-CD20 monoclonal anti-
body (rituximab) with or without cyclophosphamide for
skin disease progression and/or lung involvement, while
the other 16 patients did not receive immunosuppressive
drugs.
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Internal organ involvement was evaluated no longer
than one month before or after the skin biopsies. All
patients with SSc underwent pulmonary function tests
(PFTs) to define forced vital capacity (FVC) and diffusing
capacity for carbon monoxide (DLCO), and high reso-
lution computed tomography (HRCT) was performed to
assess lung involvement [36]. Renal involvement was
defined as a scleroderma crisis or as the presence of protein-
uria or elevation in creatinine serum level. Electrocardiog-
raphy (ECG) and echocardiography were also performed in
all patients: cardiac involvement was defined as the
presence of conduction disturbance, left ventricular
ejection fraction (LVEF) and <50%, pulmonary artery
systolic pressure (PASP) >35 mmHg on echocardiog-
raphy. Gastro-intestinal involvement was defined as
the presence of gastroesophageal reflux symptoms or
the evidence of gastrointestinal motility disturbance.
Four female healthy subjects (age range 36–55 years)
gave their informed consent to undergo forearm skin bi-
opsy, as controls.
Immunohistochemical analysis
Immunohistochemical analysis was carried out on 5-μm
thick tissue sections on polylysine-coated slides. After
deparaffinization and rehydration, antigen retrieval was
performed. Slide-mounted sections were heated in a
microwave oven at 700 watt two times for 4 min in 10
mmol/L sodium citrate buffer (pH 6.0). Quenching of
endogenous peroxidase activity was performed with
Tris-buffered saline (TBS) (pH 7.6) containing 2%
hydrogen peroxide (H2O2) for 10 min at room
temperature (RT). To prevent non-specific binding,
blocking was performed with Super block (UCS
Diagnostics, Rome, Italy) for 8 min at RT. Sections were
incubated with anti-CD3 mouse monoclonal antibodies
(mAb) (1:50 dilution; Clone PS1, Abcam, Cambridge,
MA, USA) or anti-CD20 mouse mAb (1:100 dilution;
Clone L26; Novus Biologicals, Littleton, CO, USA) or
human anti-CD138 (Syndecan-1) rabbit polyclonal anti-
bodies (Ab) (1:25 dilution; Spring Bioscience, CA, USA).
Tissues were then incubated with the Super Picture
HRP Polymer Conjugated Broad Spectrum (Invitrogen,
Carlsbad, CA, USA) for 30 min at RT and the chromo-
genic reaction was developed with 3,3′-diaminobenzi-
dine tetrahydrochloride solution (Zymed Laboratories,
South San Francisco, CA, USA). The nuclei were lightly
counterstained with hematoxylin. Negative controls
without primary Abs were performed for all reactions.
Human tonsil specimens were used as positive controls.
CD68 was immunohistochemically assessed using an
autostainer (BOND MAX III, Leica Biosystems, Newcastle,
UK), according to the manufacturer’s standard protocol,
using an anti-CD68 mouse anti-human mAb (ready to use;
clone 514H12, Leica Biosystems) [37].
Cellular infiltrates were studied in the dermis and/
or subcutaneous tissue and were classified as either
perivascular or diffuse. Positive cells were counted by
two independent observers in a total of six randomly
selected fields (total area 7.38 mm2) for each section
at × 400 magnification, under a light microscope
(Axioskop 2 plus, Zeiss). The total number of positive
cells was calculated and reported as mean ± SD,
median and range.
Statistical analysis
All analyses were carried out using SPSS 15.0 (Chicago,
IL, USA). Categorical variables were expressed as num-
bers, and quantitative variables as mean ± SD if normally
distributed, and as median plus range if not. Categorical
variables were analyzed using the chi-square (Χ2) test or
Fisher’s test, depending on sample size restrictions. Non-
normally distributed continuous data were compared
using the Mann-Whitney test and the Wilcoxon test (for
paired data). A value of p < 0.05 was considered statisti-
cally significant. Correlation was tested using Spearman’s
rank order correlation for non-normally distributed inter-
val data.
Results
Demographic, clinical and immunological characteristics
of enrolled patients with SSc
Demographic and clinical characteristics of patients with
SSc enrolled in the study are shown in Table 1.
The mean age (± SD) of the patients with SSc was 44.6 ±
15.4 years and the median disease duration was 16.0 (range
3.0–360.0) months. There were 19 patients (67.9%) with
early disease, defined as diagnosis up to 3 years after the oc-
currence of Raynaud’s phenomenon; the remaining 9 pa-
tients (32.1%) had long-standing disease. There were 20
patients (71.4%) with dSSc. The baseline mean modified
Rodnan skin score was 15.8 ± 11.3 (range 2.0–43.0). Anti-
topoisomerase antibodies (anti-Scl-70 Abs) were present in
21 (75.0%) patients and anti-centromere Abs (ACA) in 3
patients (10.7%). One patient presented with RNA polymer-
ase III autoantibody positivity; the other three patients were
ANA positive only (one with a nucleolar pattern and two
with a homogeneous pattern) (Additional file 1: Table S1).
Skin CD20+ B-cells and CD138+ plasma cell infiltrates
characterize patients with SSc based on disease duration
and subset
In all 56 cutaneous specimens from patients with SSc,
mononuclear cell infiltrates were found in a perivascular
location, predominantly in the mid and deeper portions
of the dermis. CD20+ cells were found in 17 (60.7%) out
of the 28 patients with SSc: 9 of these patients (52.9%)
had CD20+ cells in either clinically involved or
uninvolved skin, 7 (41.2%) had CD20+ cells only in the
Bosello et al. Arthritis Research & Therapy  (2018) 20:75 Page 3 of 11
involved skin and one patient with diffuse skin disease
and anti-Scl-70 Abs had CD20+ cells only in clinically
uninvolved skin. Importantly no CD20+ cells were found
in biopsy specimens from healthy volunteers.
In the subgroup that had CD20+ staining, the mean
number of CD20+ cells was higher in involved (4.7 ± 5.9)
than in uninvolved skin (1.9 ± 2.9), (p = 0.04, Table 2).
Among the 17 patients with CD20+ cells on skin biopsy,
12 patients (70.6%) had early disease, 14 (82.3%) had
diffuse skin involvement and 12 (70.6%) had anti-Scl-
70 Ab positivity. Patients with early SSc had higher
numbers of CD20+ cells (6.3 ± 6.5) than patients with
long-standing disease (1.2 ± 0.9, (p = 0.009)) in involved
skin. In clinically involved skin, patients with dSSc had
numbers of CD20+ cells (4.9 ± 6.4) comparable to patients
with lSSc (4.3 ± 4.0), but interestingly all patients with
CD20+ cells in the clinically uninvolved skin had diffuse
disease (Fig. 1).
All patients with B cells in clinically uninvolved skin
had anti-Scl-70 Abs, RNA polymerase III autoantibody
positivity or ANA positivity; none of the patients with
ACA positivity had a B cell aggregate in uninvolved skin.
The 17 patients with CD20+ cells in their skin had
shorter disease duration (33.2 ± 36.8 months), compared
to patients without B cell aggregate in skin biopsies (61.
9 ± 104.6 months), but this difference was not
statistically significant, and there was no significant
correlation between the number of CD20+ cells and
disease duration. No association emerged between the
presence of CD20+ cells and restrictive lung involvement
or heart or gastrointestinal disease.
The number of CD20+ cells in involved skin cells
directly correlated with the number of CD20+ cells in
uninvolved skin (r = 0.62, p < 0.001) and with the number
of CD3+ cells in involved skin (r = 0.4, p = 0.03).
Furthermore, CD20+ cells in involved skin were inversely
correlated with DLCO values (r = − 0.5, p = 0.01) and
with FVC values (r = − 0.5, p = 0.003).
CD138+ cells were found in 100% of involved skin
biopsies and in 89.3% of clinically uninvolved skin
samples (Table 2), but none of the healthy controls had
plasma cells in the skin.
The mean number of CD138+ cells was higher in
clinically involved skin (3.6 ± 2.3) than in uninvolved
skin (1.9 ± 1.7 (p < 0.001)) (Fig. 2). Although in patients
with early disease the number of CD138+ cells in involved
skin (4.2 ± 2.6) and in uninvolved skin (2.1 ± 1.9) was higher
than in longstanding disease (involved skin 2.6 ± 1.4,
uninvolved skin 1.7 ± 1.1), this difference was not statistically
significant. Furthermore, no statistically significant difference
was found in the mean number of CD138+ in patients with
diffuse skin disease either in involved (4.1 ± 2.6) or
uninvolved (2.1 ± 1.9) skin compared to patients with lSSc
(involved skin 2.5 ± 1.0, uninvolved skin 1.7 ± 1.0). No
differences were observed in plasma cell infiltrates in
patients with different autoantibodies specificities or in
patients with different organ involvement.
In involved skin, the number of CD138+ cells directly
correlated with the number of CD20+ cells (r = 0.6, p = 0.01)
and with the number of CD3+ cells (r = 0.5, p = 0.01),
whereas there was no significant correlation on analysis of
the non-affected skin samples.
Table 1 Demographic and clinical characteristics of patients
with SSc enrolled in the study
Characteristic Value
Age (years), mean (SD) 44.6 (15.4)
Age (years), median (range) 46.0 (20.0–67.0)
Female, number (%) 24 (85.7)
Male, number (%) 4 (14.3)
Disease duration (months), mean (SD) 44.7 (71.5)
Disease duration (months), median (range) 16.00 (3–360)
Early disease, number (%) 19 (67.9)
Long-standing disease, number (%) 9 (32.1)
Anti-Scl-70 positivity, number (%) 21 (75.0)
ACA positivity, number (%) 3 (10.7)
RNA polymerase III positivity, number (%) 1 (3.6)
ANA positivitya, number (%) 3 (10.7)
dSSc, number (%) 20 (71.4)
lSSc, number (%) 8 (28.6)
Skin score, mean (SD) 15.8 (11.3)
Skin score, median (range) 14.0 (2.0–43.0)
Activity index, mean (SD) 4.4 (2.0)
Activity index, median (range) 4.2 (1.0–8.5)
Severity index, mean (SD) 8.0 (2.6)
Severity index, median (range) 7.5 (4.0–14.0)
FVC (%), mean (SD) 87.8 ± 22.1
FVC (%), median (range) 94.0 (41.0–123.0)
DLCO (%), mean (SD) 57.3 ± 18.4
DLCO (%), median (range) 57.0 (26.0–93.0)
HRCT interstitial score, mean (SD) 7.6 (2.3)
HRCT interstitial score, median (range) 7.0 (4.0–14.0)
HRCT alveolar score, mean (SD) 6.7 (5.0)
HRCT alveolar score, median (range) 6.0 (0.0–16)
ESR, mm/h, mean (SD) 20.4 (20.3)
ESR, median (range) 12.0 (2.0–84.0)
The values are indicated as the mean (SD) and median (range) or
number (percentage)
ANA antinuclear antibodies, ACA anticentromere antibodies, anti-Scl-70 anti-
topoisomerase antibodies, dSSc diffuse skin disease, lSSc limited skin disease,
FVC forced vital capacity, DLCO diffusion lung carbon monoxide, ESR
erythrocyte sedimentation rate
aANA positivity: two patients who were ANA-positive presented with a
homogeneous pattern, and one patient presented with a nucleolar pattern
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Skin CD3+ T-lymphocyte infiltrates are differentially
presented in patients with SSc based on the skin
compartment and autoantibody positivity
CD3+ cells were found in all skin biopsies of both healthy
subjects and patients with SSc. In healthy subjects, CD3+
cell number was significantly smaller (8.0 ± 2.0) compared
to that in involved (71.7 ± 34.6, (p < 0.001)) or uninvolved
(45.7 ± 36.0, (p < 0.001)) skin from patients with SSc.
The mean number of CD3+ cells was higher in clinically
involved skin than clinically uninvolved skin, (p = 0.001)
(Table 2, Fig. 3). No statistically significant difference in
the mean number of CD3+ cells was found in skin from
patients with early compared to long-standing SSc, either
in involved or uninvolved skin (Table 2).
The mean number of CD3+ cells in involved skin was
higher in patients with dSSc (75.1 ± 35.8) than in patients
with lSSc (63.2 ± 31.7), but this difference was not
statistically significant, probably due to the wide variation
in cell numbers.
The number of CD3+ cells was comparable in involved
skin from patients with SSc regardless to anti-Scl-70 Ab
positivity. In clinically uninvolved skin biopsies, patients with
anti-Scl-70 Abs had a greater number of T lymphocytes (51.
7 ± 38.7) than anti-Scl-70 Ab-negative patients (27.7 ± 18.8,
(p = 0.05)). It is worth mentioning that the small group of
patients with ACA positivity had a smaller number of CD3+
cells in both affected and unaffected skin. The number of
CD3+ cells in involved skin directly correlated with the
number of CD3+ cells in uninvolved skin (r = 0.5, p = 0.009)
and inversely correlated with DLCO (r = − 0.4, p = 0.002),
but there was no correlation with the Rodnan skin score,
disease activity or severity scores.
Table 2 CD68+, CD3+, CD20+ and CD138+ cell counts on paired skin specimens in the 28 patients with SSc
Clinically involved skin Clinically uninvolved skin P
CD68+ mean (SD) 26.3 (8.3)a 13.6 (6.1)a 0.001
CD68+ median (range) 24.5 (12.0–40.0) 12.5 (3.0–25.0)
CD3+ mean (SD) 71.7 (34.6)a 45.7 (36.0)a 0.001
CD3+ median (range) 70.0 (7.0–146.0) 29.8 (1.0–130.0)
CD20+ mean (SD)* 4.7 (5.9)b 1.9 (2.9)b 0.04
CD20+ median (range) 2.0 (0.0–25.0) 1.0 (0.0–11.5)
CD138+ mean (SD) 3.6 (2.3)a 1.9 (1.7)c < 0.001
CD138+ median (range) 3.0 (0.5–11.5) 1.5 (0.0–9.0)
The values are the mean (SD) and median (range)
aMean (SD) and median (range) of CD68+, CD3+, CD138+ in clinically involved skin (forearm) and of CD68+ and CD3+ in clinically uninvolved skin (buttock) refers
to the duplicate skin samples from patients
bMean (SD) and median (range) of CD20+ was calculated considering only the 17 patients (60.7%) that had almost one CD20+ cell in clinically involved skin or in
clinically uninvolved skin
cMean (SD) and median (range) of CD138+ in clinically uninvolved skin was calculated considering 25 out of 28 (89.3%) patients with CD138 + cells in uninvolved
skin specimens
a b
Fig. 1 CD20 cell staining in involved and uninvolved skin from a patient with systemic sclerosis (SSc). a Cellular infiltrate in involved skin (distal
forearm biopsy) from a patient with early anti-Scl-70+ diffuse SSc showing an appreciable number of CD20+ cells in perivascular areas. b
Uninvolved skin (buttock biopsy) from the same patient showing the presence of a smaller number of CD20+ cells around blood vessels. Original
magnification × 400 (a and b). Nuclei were counterstained by hematoxylin. Bottom insets show the infiltrating cells at a lower magnification (×
200). Insets at the top of the figures show hematoxylin and eosin (H&E) staining of involved and uninvolved skin (× 50)
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Skin CD68+ macrophage infiltrates are differentially
presented in patients with SSc based on the skin
compartment
Using paired skin samples, CD68+ cell count was
significantly higher in clinically involved (26.3 ± 8.3)
compared to uninvolved skin from patients with SSc (13.6
± 6.1) (p = 0.001) (Fig. 4), the CD68+ cells having a
preferential perivascular distribution within the dermis.
Grouping patients with SSc according to the disease
subset, we found that CD68+ cell count was significantly
higher in clinically uninvolved skin from patients with SSc
with a diffuse phenotype (14.8 ± 5.8) compared to patients
with SSc with limited disease (8.3 ± 4.7) (p = 0.05),
whereas there was no difference in macrophage infiltrate
when comparing involved skin samples from patients with
dSSc (27.2 ± 7.8) to skin samples from patients with lSSc
(22.3 ± 11.7) (p = 0.78). The number of CD68+ cells was
comparable in involved skin from patients with SSc
despite anti-Scl-70 Ab positivity. In clinically uninvolved
skin, patients with anti-Scl-70 Abs had a greater number
of CD68+ cells (15.0 ± 5.1) than patients with SSc without
anti-Scl-70 Abs (4.0 ± 1.4) (p = 0.02, Table 2).
Cell infiltrate and skin score progression: the role of B
cells
During follow up 12 patients were treated with rituxi-
mab with or without cyclophosphamide because of the
progression of skin disease, while 16 patients did not re-
ceive any treatments because no progression of skin
score was present at the time of biopsy (Table 3). At
study entry, patients with SSc had comparable immuno-
histological findings in terms of CD68, CD3, CD20 and
CD138 cells in clinically affected and unaffected skin
samples after treatment stratification. However, treated
patients had a decrease in skin score during follow up
from 21.1 ± 10.9 to 11.2 ± 6.2 (p = 0.03), and all but one
a b
Fig. 2 CD138 cell staining in involved and uninvolved skin from a patient with systemic sclerosis (SSc). a Involved skin (distal forearm biopsy)
from a patient with an early anti-Scl-70+ diffuse SSc showing an appreciable number of CD138+ cells in perivascular areas. b Uninvolved skin
(buttock biopsy) of the same patient showing the presence of a smaller number of CD138+ cells around blood vessels. Original magnification ×
400 (a and b). Nuclei were counterstained by hematoxylin. Bottom insets show the infiltrating cells at a lower magnification (× 200). Insets at the
top of the figures show hematoxylin and eosin (H&E) staining of involved and uninvolved skin (× 50)
a b
Fig. 3 CD3 cell staining in involved and uninvolved skin from a patient with systemic sclerosis (SSc). a Involved skin (distal forearm biopsy) from a
patient with early anti-Scl-70+ diffuse SSc showed massive infiltration with CD3+ cells in perivascular areas. b Uninvolved skin (buttock biopsy)
from the same patient showing the presence of a smaller number of CD3+ cells around blood vessels. Original magnification × 400 (a and b).
Nuclei were counterstained by hematoxylin. Bottom insets show the infiltrating cells at a lower magnification (× 200). Insets at the top of the
figures show hematoxylin and eosin (H&E) staining of involved and uninvolved skin (× 50)
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experienced a response >20% in the skin score. The clin-
ical response in term of skin score improvement was not
associated with the rate of baseline cell infiltrate.
Among the 16 patients that did not receive immuno-
suppressive therapy during the follow up, 9 patients had
a stable skin score or worsening of the score was less
than 20% after 6.5 ± 0.8 months, while 7 patients (43.
7%) had more than 20% worsening of the skin score.
The baseline and follow-up skin score in the latter
patients were respectively 11.9 ± 10.6 and 15.7 ± 10.3
(p = 0.02). Among the 17 patients with B cell skin
infiltrate at baseline, 8 patients were treated due to pro-
gressive skin involvement and 7 untreated patients had
worsening during follow up. In the remaining two un-
treated patients with baseline B cell skin infiltrate, the skin
score remained stable during the follow up.
In the 16 untreated patients, 9 patients with sclero-
derma (56.2%) had CD20+ cell skin infiltrate at baseline:
7 of them (77.8%) experienced worsening of the skin
score, while none of the patients without CD20+ cells in
the skin specimens experienced worsening of the skin
score (Fisher’s test, p = 0.03). The mean number of
CD20+ cells in involved skin from the seven patients
with worsening of the skin score was higher than that in
patients without worsening, but the difference was not
statistically significant. Furthermore, the mean number
of baseline CD138+ cells in involved skin (4.6 ± 3.6) and
uninvolved (2.6 ± 1.1) skin biopsies was slightly higher
in patients with skin progression compared to patients
without skin worsening (involved skin 2.7 ± 1.1,
uninvolved skin 1.7 ± 1.3), (p value not significant).
The mean number of baseline CD3+ cells in affected and
unaffected skin of patients with a worsening of skin score
(involved skin 79.3 ± 48.3, uninvolved skin 44.8 ± 37.0) was
comparable to the mean number of CD3+ cells in patients
with stable skin score (involved skin 78.6 ± 20.0,
uninvolved skin 50.3 ± 31.9), (p value not significant in
both comparisons).
Comparable results were obtained for CD68 staining; in
fact, the mean number of baseline CD68+ cells in affected
and unaffected skin in patients with skin progression
(involved skin 31.3 ± 9.1, uninvolved skin 10.3 ± 4.7) was
similar to the mean number of CD68+ cells in patients
with a stable skin score (involved skin 24.7 ± 4.5,
uninvolved skin 14.3 ± 9.3), (p value not significant in
both comparisons).
Discussion
A cutaneous cellular infiltrate is a frequent histopatho-
logic finding in SSc [3, 6, 7, 10]. Cutaneous mononuclear
cell infiltrates [3–12] may play a major role in starting
and to mediating dermal sclerosis through their effects
on fibroblasts [1].
In our study, T lymphocytes and macrophages were
found in all cutaneous specimens from patients with SSc
that were analyzed, predominantly in a perivascular loca-
tion in the mid and/or deeper portion of the dermis. In
previous studies, mononuclear cell infiltrates, including
macrophages [3, 6–9] and T lymphocytes [3, 6, 8–12],
with an increased number also of mast cells [3, 5, 6],
were reported in SSc skin biopsies, above all in the early
phases of the disease. In particular, Fleischmajer and co-
workers [6] found that only 49% of patients with SSc
had diffuse or perivascular cellular infiltrates in the der-
mis or subcutaneous tissue; the cells were identified as
lymphocytes, plasma cells and macrophages. In this
a b
Fig. 4 CD68 cell staining in involved and uninvolved skin from a patient with systemic sclerosis (SSc). a Involved skin (distal forearm biopsy) from
a patient with early anti-Scl-70+ diffuse SSc showed an infiltrate of CD68+ cells (red) in perivascular areas. b Uninvolved skin (buttock biopsy) from
the same patient showing the presence of a smaller number of CD68+ cells around blood vessels. Original magnification × 400 (a and b). Nuclei
were counterstained by hematoxylin. Insets at the bottom of the figures show the infiltrating cells at a lower magnification (× 200). Insets at the
top of the figures show hematoxylin and eosin (H&E) staining of involved and uninvolved skin (× 50)
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cohort, about 40% of the patients had early SSc and we
did not find any associations with disease duration or
immunological characteristics.
Evidence of cellular skin infiltrate has been reported
previously in another study [10], in which up to 50% of
the biopsies had relevant dermal mononuclear infiltration,
but low/mild infiltrate was found in the other specimens
[10]. The patients with relevant infiltrate frequently pre-
sented with diffuse disease, shorter disease duration [10,
11] and a higher skin thickening score [10]. The majority
of T cells present in the skin infiltrate were activated T
lymphocytes [10, 11], suggesting that early CD69+ T cells
may actively participate in cell-cell contact with fibroblasts
to induce fibrosis in skin lesions [11]. In our study, all
specimens had relevant mononuclear infiltration. This dis-
crepancy between the results of the previous studies [10]
and our data may be due to differences in disease duration
or in the area of the body from which the specimens were
taken. Furthermore, genome-wide gene expression profil-
ing studies of SSc skin biopsies have demonstrated wide
heterogeneity, which can be quantitatively measured by
DNA microarrays [13, 38–40]. Four specific gene expres-
sion signatures in both lesional and non-lesional skin bi-
opsies have been identified in scleroderma compared to
healthy controls [39].
Interestingly, in our study, the inflammatory cell infil-
tration was also present in the clinical uninvolved cuta-
neous specimens, in which the skin apparently did not
have any clinical signs of thickness and sclerosis. This
finding is in agreement with the indistinguishable pat-
tern of gene expression found in clinically affected and
clinically unaffected tissue from patients with SSc, which
was clearly different from the gene expression in healthy
subjects [13]. Our immunohistochemical data indicated
that in patients with SSc the skin, even when considered
as clinically uninvolved, is affected by an inflammatory
Table 3 Clinical and histological characteristics according to immunosuppressive/immunomodulatory treatment and clinical






Age (years), mean (SD) 39.3 (13.9) 48.6 (16.2) ns
Female/male, number 10/2 14/2 ns
Disease duration (months), mean (SD) 42.8 (100.3) 45.8 (41.5) ns
Early/longstanding disease, number 10/2 9/7 ns
dSSc/lSSc number 11/1 9/7 0.05
Skin score baseline, mean (SD) 21.1 (10.9) 11.9 (10.6) 0.03
Anti-scl-70 antibodies positivity, number (%) 10 11 ns
ACA positivity, number 0 3
ANA positivity, number 2 2
Presence of CD20+ cell in skin biopsy, number (%)a 8 (66.7) 9 (56.3) ns
CD20+ in clinically involved skin, mean (SD) 2.3 (3.1) 3.4 (6.3) ns
CD20+ in clinically uninvolved skin, mean (SD) 1.5 (3.3) 0.9 (1.6) ns
CD138+ in clinically involved skin, mean (SD) 3.5 (1.5) 3.8 (2.9) ns
CD138+ in clinically uninvolved skin, mean (SD) 1.7 (1.8) 2.2 (2.1) ns
CD3+ in clinically involved skin, mean (SD) 62.0 (28.9) 78.9 (37.4) ns
CD3+ in clinically uninvolved skin, mean (SD) 43.7 (40.2) 47.2 (33.9) ns
CD68+ in clinically involved skin, mean (SD) 25.3 (9.1) 38.0 (7.4) ns
CD68+ in clinically uninvolved skin, mean (SD) 14.4 (5.7) 12.3 (6.9) ns
Skin score after 6-month follow up, mean (SD) 11.3 (6.9) 13.0 (10.9) ns
Patients with decrease >20% of skin score after 6-month follow upb 11 (91.7) 3 (18.7) 0.01
Patients with worsening >20% of skin score after 6-month follow up 0 (0.0) 7 (56.3) 0.01
Patients with CD20 + cells on skin biopsy 0 (0.0) 7 (77.8)
Patients without CD20+ cells on skin biopsy 0 (0.0) 0 (0.0)
The values are indicated as the mean (SD) or number (percentage) according to the data distribution
SSc systemic sclerosis, ANA antinuclear antibodies, ACA anticentromere antibodies, anti-Scl-70 anti-topoisomerase antibodies, dSSc diffuse skin disease, lSSc limited
skin disease, ns not significant
aPresence of at least one CD20+ cell in involved or uninvolved skin biopsy
bIn this subgroup, six patients had CD20+ cells in uninvolved skin and were treated with immunosuppressive drug, while none of the untreated patients had
CD20+ cells (p = 0.002)
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process, suggesting that pathological changes can be
detected even before the onset of skin sclerosis. Gene
expression profiling studies have confirmed an altered
signature in unaffected skin in patients with systemic scler-
osis [13, 16], highlighting the truly systemic inflammatory
nature of the disease. Interestingly, in our study, the num-
ber of CD68+, CD3+, CD20+ and CD138+ cells was higher
in involved skin than in uninvolved skin, suggesting a local
role for these cells in accelerating the fibrogenic processes,
that lead to clinical skin modifications. The role of
macrophages in different target organs in patients with SSc
has been recently demonstrated [15, 41] and confirmed in
multiple cohorts with skin disease, showing that the gene
expression of several activated macrophage markers are
elevated in the skin in SSc [14]. Activated macrophages
likely play a pivotal role in the pathogenesis of SSc by
activating fibroblasts, but as these cells are plastic and
readily modulated by the local tissue microenvironment,
the cytokine milieu determined also by the presence of B
and T lymphocytes, dendritic cells, endothelial cells and
fibroblasts might play a role in the pathogenesis of the
fibrotic process in the skin [41].
The role of T cells in SSc is already accepted [42]. In
this regard, all SSc specimens examined in our study
had significant CD3+ cell infiltrate mainly in clinically
involved but also in uninvolved skin, supporting the
concept that the dermal T lymphocytes play a key role
in local pathogenic events in SSc by cytokine production
and that lymphocyte/fibroblast interaction in the skin is
important in the pathophysiology of SSc. However, the
main clue to the specific importance of the immune cell
infiltrates did arise from the longitudinal assessment of
the course of the skin involvement. The mechanistic
exploration of the pathogenic infiltrate still needs to be
defined. The positive response to rituximab in a
subgroup of patients with SSc, regardless of the baseline
presence of B cell skin infiltrates, indirectly supports the
notion that there might be a complex relationship
among all mononuclear cells in determining clinical
modification and fibrosis in scleroderma and probably
the T and B cell crosstalk can have a role in promoting
the fibrotic process.
Even though a recent analysis of DNA microarrays of
cutaneous biopsies from patients with dSSc demonstrated
higher expression of clusters of genes in CD20+ cells [13],
in some immunohistochemical studies the B cells were
rare or absent [3, 8–10]. Recently, the analysis of B cell
infiltrate performed in skin biopsies from patients treated
with anti-CD20 therapy demonstrated improvement in
the skin score and stabilization of FVC, DLCO and clinical
symptoms [17–21, 23]. In our study, B cell infiltrate seems
to be characteristic of the skin in scleroderma, in fact
CD20+ and CD138+ cells were absent in all specimens
from healthy subjects. B lymphocytes were detected in up
to 61% of patients with SSc and the mean number of
CD20+ and CD138+ cells was lower than the number of
CD3+ and CD68+ cells. Fifty percent of these patients had
B cells both in involved and in uninvolved skin, while the
other 50% had B cells only in involved skin, while plasma
cells were present in all involved skin and in all but three
samples of clinically uninvolved skin. The presence of
plasma cells suggests that specific chemotaxis or local
maturation of memory B cells had occurred. The wide
variability in the identification of B cells in skin biopsies in
our study and in other studies could be related to the
different cell signatures previously reported [39].
Certainly, the clinical effects seem not to depend upon the
cell numbers found in the skin biopsy samples.
The great majority of patients with SSc who had
CD20+ cells on skin biopsies had anti-Scl-70 Ab positiv-
ity or early disease or diffuse skin involvement. Patients
with early disease had a greater number of CD20+ cells
in involved skin compared with patients with long-
standing disease, and the presence of CD20+ cells in
uninvolved skin seems to be characteristic of patients
with dSSc. Our sample size was not large enough to
draw definite conclusions, but our data suggest that B
cells are associated with the classical negative prognostic
factor of scleroderma such as diffuse phenotype and
antiscl-70 Ab positivity. Among the various immune
cells, B cells appear to be the only ones linked to pro-
gression of skin involvement over time.
Albeit the number of patients enrolled in this study
was limited, the worsening of skin involvement in the
group of patients with CD20+ cells on skin biopsy after
6-month follow up suggests a possible prognostic value
of B cell presence in the progression of skin involve-
ment. No prognostic role was evident for plasma cells,
suggesting that very likely they were already there, and
that the arrival of the new B cells was the most import-
ant event for the diseased skin. The presence of B cells
in the majority, but not in all patients, indicates an im-
portant, though not essential role for cutaneous B cells
in more aggressive scleroderma disease, above all during
the earliest phases when the inflammatory process and
cell-cell interactions very likely play an essential role in
the development of fibrosis over time. B cells in the skin
may be involved in the initiation and expansion of the
SSc inflammatory process. Of interest, even plasma cells
were present either in the involved or the uninvolved
skin and in 10 patients in this cohort on analysis of the
peripheral blood B cell subsets, we found that the num-
ber of CD20+ and CD138+ cells in the skin specimens
correlated directly with the percentage of circulating
CD27+CD38+ plasmablasts (unpublished data). Either
resident and circulating B cells can determine, with their
multiple functions as Ab-producing cells, antigen pre-
senting cells and profibrotic and proinflammatory
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cytokine (IL-6, IL-4, transforming growth factor (TGF)-β)-
secreting cells [1, 43], an autoimmune milieu that could
be of great impact in the development of fibrosis. B cells
directly stimulate fibroblasts by a direct contact-based
mechanism [44] and a plethora of soluble factors present
in the inflammatory skin condition contributes to the
commitment of B cells in autoantibody-producing plasma
cells, which, again, can directly stimulate fibroblasts.
The limited number of patients with scleroderma and
of healthy controls in this study did not allow us to infer
robust correlation with disease phenotype and organ in-
volvement, but further studies on sequential biopsies
after therapy could allow us to investigate temporal asso-
ciations with different types of cell infiltrates, and to test
correlation with the characteristics of inflammatory infil-
trate with fibrotic involvement, such as the collagen
score and myofibroblast score.
Conclusions
These results highlight that a subgroup of patients with
SSc exhibit an imbalance in B cell infiltrate and that cu-
taneous mononuclear cells of the innate and adaptive
immune system may play a role in mediating dermal fi-
brosis in different stages of scleroderma disease and in
patients with diffuse skin involvement. Therapeutic ap-
proaches decreasing the numbers of cutaneous lympho-
cytes, in particular B cells, and/or interfering with their
functions might prove useful in the management of cu-
taneous involvement in SSc from the earliest phases of
the disease.
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